Impact of evergreening on patients and health insurance: a meta analysis and reimbursement cost analysis of citalopram/escitalopram antidepressants

BACKGROUND: "Evergreening" refers to the numerous strategies whereby owners of pharmaceutical products use patent laws and minor drug modifications to extend their monopoly privileges on the drug. We aimed to evaluate the impact of evergreening through the case study of the antidepressant...

Descripción completa

Detalles Bibliográficos
Autores principales: Alkhafaji, Ali A, Trinquart, Ludovic, Baron, Gabriel, Desvarieux, Moïse, Ravaud, Philippe
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2012
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3520785/
https://www.ncbi.nlm.nih.gov/pubmed/23167972
http://dx.doi.org/10.1186/1741-7015-10-142

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3520785/
https://www.ncbi.nlm.nih.gov/pubmed/23167972
http://dx.doi.org/10.1186/1741-7015-10-142

Ejemplares similares